Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

0.6501
-0.1752-21.23%
Post-market: 0.67330.0232+3.57%19:59 EST
Volume:622.73K
Turnover:528.16K
Market Cap:2.13M
PE:-0.05
High:0.8600
Open:0.8600
Low:0.6500
Close:0.8253
52wk High:17.80
52wk Low:0.6500
Shares:3.28M
Float Shares:2.42M
Volume Ratio:9.89
T/O Rate:25.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8100
EPS(LYR):-30.9580
ROE:-27725.96%
ROA:-31.66%
PB:-1.01
PE(LYR):-0.02

Loading ...

HCW Biologics Licenses TRBC Asset to China JV Trimmune

TIPRANKS
·
Feb 13

HCW Biologics, WY Biotech close first round of financing for joint venture

TIPRANKS
·
Feb 13

HCW Biologics and Wy Biotech Announce Closing of First Round of Financing for Newly Formed Joint Venture Trimmune

THOMSON REUTERS
·
Feb 13

Press Release: HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

Dow Jones
·
Feb 13

HCW Biologics files to sell 9.52M shares of common stock, warrants

TIPRANKS
·
Feb 12

HCW Biologics files to sell 3.4M shares of common stock for holders

TIPRANKS
·
Jan 10

HCW Biologics Raises $3.8 Million Through Warrant Exercise and Equity Issuance

Reuters
·
Jan 01

HCW Biologics Secures $4M Through Warrant Exercise

TIPRANKS
·
Nov 21, 2025

HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants

Reuters
·
Nov 21, 2025

BRIEF-Hcw Biologics Announces Warrant Inducement Agreement

Reuters
·
Nov 19, 2025

HCW Biologics Inc - Announces Warrant Inducement Agreement

THOMSON REUTERS
·
Nov 19, 2025

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
Nov 19, 2025

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

GlobeNewswire
·
Nov 18, 2025

HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate

Benzinga
·
Nov 15, 2025

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters
·
Nov 10, 2025

HCW Biologics announces data presented for TCE Program based on TRBC platform

TIPRANKS
·
Nov 07, 2025

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 07, 2025

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Oct 22, 2025

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire
·
Oct 16, 2025

HCW Biologics Granted Nasdaq Extension to Regain Compliance with Listing Rules

Reuters
·
Oct 16, 2025